Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:ELEV NASDAQ:HYPD NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.51-3.6%$11.46$5.01▼$18.70$80.80M0.22105,707 shs19,547 shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AHYPDHyperion DeFi$11.55-0.1%$8.86$0.85▼$47.33$65.78M2.51.95 million shs1.88 million shsQNCXQuince Therapeutics$1.62+1.3%$1.68$0.69▼$2.45$87.01M0.99227,270 shs555,007 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-1.49%-1.97%-2.85%+53.08%+22.84%ELEVElevation Oncology0.00%0.00%0.00%-4.35%-40.05%HYPDHyperion DeFi-22.83%+78.40%+60.56%+65.85%-73.08%QNCXQuince Therapeutics0.00%+1.91%-5.33%+17.65%+117.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.51-3.6%$11.46$5.01▼$18.70$80.80M0.22105,707 shs19,547 shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AHYPDHyperion DeFi$11.55-0.1%$8.86$0.85▼$47.33$65.78M2.51.95 million shs1.88 million shsQNCXQuince Therapeutics$1.62+1.3%$1.68$0.69▼$2.45$87.01M0.99227,270 shs555,007 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-1.49%-1.97%-2.85%+53.08%+22.84%ELEVElevation Oncology0.00%0.00%0.00%-4.35%-40.05%HYPDHyperion DeFi-22.83%+78.40%+60.56%+65.85%-73.08%QNCXQuince Therapeutics0.00%+1.91%-5.33%+17.65%+117.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.80Moderate Buy$21.0082.45% UpsideELEVElevation Oncology 2.00Hold$2.62616.89% UpsideHYPDHyperion DeFi 2.00Hold$2.00-82.68% DownsideQNCXQuince Therapeutics 3.18Buy$8.14402.65% UpsideCurrent Analyst Ratings BreakdownLatest ELEV, QNCX, HYPD, and ATRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025QNCXQuince TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/12/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$9.00 ➝ $8.008/5/2025QNCXQuince TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform8/5/2025QNCXQuince TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.008/5/2025QNCXQuince TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$9.007/17/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.63N/AN/A($16.89) per share-0.68ELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AHYPDHyperion DeFi$44.44K1,480.20N/AN/A($695.52) per share-0.02QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)ELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%11/4/2025 (Estimated)HYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AQNCXQuince Therapeutics-$56.83M-$1.09N/AN/AN/AN/A-187.49%-42.47%11/12/2025 (Estimated)Latest ELEV, QNCX, HYPD, and ATRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/11/2025Q2 2025QNCXQuince Therapeutics-$0.28-$0.34-$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.701.70ELEVElevation Oncology0.6719.4019.40HYPDHyperion DeFi0.200.910.91QNCXQuince Therapeutics1.455.005.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%ELEVElevation Oncology83.70%HYPDHyperion DeFi25.84%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%ELEVElevation Oncology8.10%HYPDHyperion DeFi10.86%QNCXQuince Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableELEVElevation Oncology4059.22 million54.43 millionOptionableHYPDHyperion DeFi405.70 million5.08 millionNo DataQNCXQuince Therapeutics6053.71 million44.69 millionOptionableELEV, QNCX, HYPD, and ATRA HeadlinesRecent News About These CompaniesQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.14 Consensus Target Price from AnalystsSeptember 12, 2025 | americanbankingnews.comQuince Therapeutics to Host Virtual Investor Day on October 2, 2025September 11, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.com806,780 Shares in Quince Therapeutics, Inc. $QNCX Bought by Ieq Capital LLCSeptember 3, 2025 | marketbeat.comQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Raised to "Hold" at Zacks ResearchAugust 30, 2025 | marketbeat.comQuince Therapeutics Inc News (QNCX) - Investing.comAugust 22, 2025 | investing.comQNCX Q3 EPS Estimate Lifted by Brookline Capital ManagementAugust 17, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral CapitalAugust 17, 2025 | marketbeat.comQNCX FY2029 EPS Increased by Brookline Capital ManagementAugust 16, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 16, 2025 | marketbeat.comQuince Therapeutics price target lowered to $8 from $9 at Citizens JMPAugust 12, 2025 | msn.comQuince Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | businesswire.comJMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform RecommendationAugust 5, 2025 | msn.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...July 12, 2025 | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10, 2025 | businesswire.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?By Chris Markoch | August 30, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025ELEV, QNCX, HYPD, and ATRA Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$11.51 -0.43 (-3.60%) Closing price 04:00 PM EasternExtended Trading$11.79 +0.28 (+2.43%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Hyperion DeFi NASDAQ:HYPD$11.55 -0.01 (-0.09%) As of 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Quince Therapeutics NASDAQ:QNCX$1.62 +0.02 (+1.25%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
